山东省医保谈判药品应用现状及可及性分析

范其鹏, 李浩铭

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (9) : 120-123.

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (9) : 120-123. DOI: 10.19546/j.issn.1674-3830.2022.9.025
医药经纬

山东省医保谈判药品应用现状及可及性分析

  • 范其鹏1, 李浩铭2
作者信息 +

Analysis on the Current Situation and Accessibility of National and Provincial Negotiated Drugs in Shandong Province

Author information +
文章历史 +

摘要

本文以山东省为例,研究2016年—2019年医保药品谈判情况,对药品采购量、采购额、配送时间以及药品可及性等情况进行分析,发现药品谈判提升了公立医疗机构和零售药店药品采购量、采购额,谈判后药品价格降幅明显,在采购量提升和价格下降的双重影响下,药品可及性得到提升。建议持续推进定点医疗机构和零售药店“双通道”管理机制建设,进一步提升谈判药品可及性。

Abstract

Taking Shandong Province as an example, this paper studies the national, provincial drug negotiations from2016to2019, analyzes the drug purchase volume, purchase amount, delivery time as well as drug availability, finds that drug negotiation has improved the drug purchase volume, purchase amount of public medical institutions, retail pharmacies. Drug prices after the negotiation dropped significantly, under the dual influence of the increase in purchase volume, the decline in prices, the availability of drugs has been improved. It is recommended to continue to promote the construction of a "dual-channel" management mechanism for designated medical institutions, retail pharmacies to further improve the availability of negotiated drugs

关键词

谈判药品 / 山东省 / 可及性

Key words

negotiated drugs / Shandong Province / accessibility

引用本文

导出引用
范其鹏, 李浩铭. 山东省医保谈判药品应用现状及可及性分析[J]. 中国医疗保险. 2022, 0(9): 120-123 https://doi.org/10.19546/j.issn.1674-3830.2022.9.025
Analysis on the Current Situation and Accessibility of National and Provincial Negotiated Drugs in Shandong Province[J]. China Health Insurance. 2022, 0(9): 120-123 https://doi.org/10.19546/j.issn.1674-3830.2022.9.025
中图分类号: F840.684C913.7   

参考文献

[1] 赖少清. 癌症的现状与困境、希望与出路——基于2017年、2018年全球癌症发病与防控态势分析[J].医学与哲学,2019,40(12):20-23.
[2] 田红,肖桂芝,刘永贵.抗肿瘤药物市场分析[J].现代药物与临床,2013,28(03):424-427.
[3] 张萍萍,朱虹,刘兰茹,曲超.基于靶向药物的医保药品谈判实践研究[J].中国卫生事业管理,2016,33(04):275-278.
[4] 陈金燃,郭凯宁,陈纯,谢焜,张勇,林永顺,陈新榕,丁榕芳.2018-2019年福建省国家谈判药品患者用药可及性调研分析[J].中国医疗保险,2020(12):59-64.
[5] 王海银,丛鹂萱,谢春艳,等.我国创新药品医保支付改革的进展及思考[J].卫生经济研究,2021,38(01):47-49.
[6] 马勇,刘梦娜,艾丹丹,等.加拿大卫生技术评估助力医保药品准入的启示[J].中国医疗保险,2022(06):125-127.

Accesses

Citation

Detail

段落导航
相关文章

/